The pharmacokinetic profile of a new 800-mg tablet of nonanimal chondroitin sulfate (CS) (Mythocondro®, 800-mg tablets, Gnosis S.p.A., Italy) was investigated vs an animal CS in healthy volunteers for a total period of 48 hours. After a single 2400-mg dose of the test and the reference formulation, total CS, the compositional disaccharides (ΔDi6S, ΔDi4S and ΔDi0S), and the overall charge density were quantified in plasma. The safety and tolerability profile after a single dose of this new nonanimal CS tablets was excellent. After baseline-corrected concentrations, an overall greater plasma concentration was observed after 24 hours of ∼44% and after 48 hours of ∼45% from administration of nonanimal when compared to animal-derived CS. Moreover, nonanimal CS increases the specific sulfation in the 6-position of N-acetyl-galactosamine in human plasma CS and, as a consequence, the overall charge density, reaching double values (0.91), after 48 hours compared to bovine CS and to endogenous CS. In conclusion, nonanimal CS, possessing a lower molecular weight than an animal-derived sample, produces a greater CS concentration for a more prolonged period of time in plasma and an increase in charge density and specific 6-sulfation of endogenous plasma CS.

Oral bioavailability and pharmacokinetic of non-animal chondroitin sulfate and its constituents in healthy male volunteers / Volpi, N; Mantovani, Veronica; Galeotti, Fabio; Bianchi, D; Straniero, V; Valoti, E; Miraglia, N.. - In: CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT. - ISSN 2160-7648. - 8:3(2019), pp. 336-345. [10.1002/cpdd.587]

Oral bioavailability and pharmacokinetic of non-animal chondroitin sulfate and its constituents in healthy male volunteers

Volpi N;MANTOVANI, VERONICA;GALEOTTI, FABIO;
2019

Abstract

The pharmacokinetic profile of a new 800-mg tablet of nonanimal chondroitin sulfate (CS) (Mythocondro®, 800-mg tablets, Gnosis S.p.A., Italy) was investigated vs an animal CS in healthy volunteers for a total period of 48 hours. After a single 2400-mg dose of the test and the reference formulation, total CS, the compositional disaccharides (ΔDi6S, ΔDi4S and ΔDi0S), and the overall charge density were quantified in plasma. The safety and tolerability profile after a single dose of this new nonanimal CS tablets was excellent. After baseline-corrected concentrations, an overall greater plasma concentration was observed after 24 hours of ∼44% and after 48 hours of ∼45% from administration of nonanimal when compared to animal-derived CS. Moreover, nonanimal CS increases the specific sulfation in the 6-position of N-acetyl-galactosamine in human plasma CS and, as a consequence, the overall charge density, reaching double values (0.91), after 48 hours compared to bovine CS and to endogenous CS. In conclusion, nonanimal CS, possessing a lower molecular weight than an animal-derived sample, produces a greater CS concentration for a more prolonged period of time in plasma and an increase in charge density and specific 6-sulfation of endogenous plasma CS.
24-lug-2018
8
3
336
345
Oral bioavailability and pharmacokinetic of non-animal chondroitin sulfate and its constituents in healthy male volunteers / Volpi, N; Mantovani, Veronica; Galeotti, Fabio; Bianchi, D; Straniero, V; Valoti, E; Miraglia, N.. - In: CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT. - ISSN 2160-7648. - 8:3(2019), pp. 336-345. [10.1002/cpdd.587]
Volpi, N; Mantovani, Veronica; Galeotti, Fabio; Bianchi, D; Straniero, V; Valoti, E; Miraglia, N.
File in questo prodotto:
File Dimensione Formato  
cpdd.587.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 537.69 kB
Formato Adobe PDF
537.69 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1174877
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 4
social impact